Open Orphan (LON: ORPH) has completed the arrangements for the demerger of non-core infectious disease assets in the form of Poolbeg Pharma, which will seek an AIM admission and raise cash to finance development. However, Open Orphan shareholders will not be getting their hands on the shares immediately.
Shareholders on the Open Orphan register on 17 June will be given one Poolberg share for every 2.98 Open Orphan shares they own. The influenza treatment and vaccines developer will be making...
You are unauthorized to view this page.